Susceptibility Gene Identified for Idiopathic Pulmonary Arterial Hypertension
|
By LabMedica International staff writers Posted on 14 Apr 2020 |

Image: The 96-capillary 3730xl DNA Analyzer is the Gold Standard for high throughput genetic analysis and used for Sanger sequencing (Photo courtesy of Thermo Fisher Scientific)
Idiopathic pulmonary arterial hypertension (IPAH) is a lung disorder characterized by high blood pressure in the pulmonary arteries. In this instance, “idiopathic” means that the cause of the pulmonary artery hypertension is unknown.
Pulmonary arterial hypertension is rare, with about 1,000 new diagnoses in the USA each year. IPAH is a hard disorder to diagnose because some people do not have symptoms, and when there are symptoms of IPAH, they are similar to those of other heart and lung disorders.
Scientists at the Peking Union Medical College Hospital (Beijing, China) and their colleagues enrolled 230 patients with IPAH from two referral pulmonary hypertension centers in China. Eligible patients had no BMPR2 variants and were compared with 968 healthy control participants. Data were collected from January 1, 2000, to July 31, 2015, and analyzed from August 1, 2015, to May 30, 2018.
The investigators sequenced the genomes of 42 patients with IPAH, none of whom had BMPR2 variants. The team also performed whole genome sequencing (WGS), Sanger sequencing on an ABI 3730 automated sequencer (Applied Biosystems, Courtaboeuf, France), right heart catheterization, pulmonary vasodilator testing, plasmid construction, cell culture and transfection, measurement of 6-Keto–prostaglandin F1α levels using an enzyme-linked immunosorbent assay (ELISA) kit (Cayman Chemical, Ann Arbor, MI, USA).
After filtering, the scientists uncovered 1,986 rare variants affecting 1,772 candidate genes. Most of these alterations were present only in a single person, but 15 genes were altered in three or more people. Of those, PTGIS, MACF1, GTF3C1, and ABCA3 are expressed in the lung. As PTGIS encodes prostaglandin synthase, which is involved in prostaglandin production, the team suspected it might be the most relevant of those 15 genes. In a replication cohort of 188 patients with IPAH, they uncovered additional patients with PTGIS variants. In all, 14 patients harbored one of three rare PTGIS variants.
The three rare PTGIS variants: A447T, R252Q, and c.521 +1G>A, are all located in conserved regions of the gene and are predicted by in silico analysis to be deleterious. Functional studies found that the PTGIS splicing variant affects the gene's transcription, as it led to exon skipping and an in-frame deletion. The two missense variants, meanwhile, led to impaired enzyme activity, decreased prostaglandin production, and increased cell death of pulmonary microvascular endothelial cells.
The authors concluded that they had identified three rare loss-of-function variants in the PTGIS gene from two independent cohorts with IPAH. The genetic variants of PTGIS predispose pulmonary vascular responses to the iloprost stimulation. These findings suggest that PTGIS variants may be involved in the pathogenesis of IPAH. The study was published on April 1, 2020 in the journal JAMA Cardiology.
Related Links:
Peking Union Medical College Hospital
Applied Biosystems
Cayman Chemical
Pulmonary arterial hypertension is rare, with about 1,000 new diagnoses in the USA each year. IPAH is a hard disorder to diagnose because some people do not have symptoms, and when there are symptoms of IPAH, they are similar to those of other heart and lung disorders.
Scientists at the Peking Union Medical College Hospital (Beijing, China) and their colleagues enrolled 230 patients with IPAH from two referral pulmonary hypertension centers in China. Eligible patients had no BMPR2 variants and were compared with 968 healthy control participants. Data were collected from January 1, 2000, to July 31, 2015, and analyzed from August 1, 2015, to May 30, 2018.
The investigators sequenced the genomes of 42 patients with IPAH, none of whom had BMPR2 variants. The team also performed whole genome sequencing (WGS), Sanger sequencing on an ABI 3730 automated sequencer (Applied Biosystems, Courtaboeuf, France), right heart catheterization, pulmonary vasodilator testing, plasmid construction, cell culture and transfection, measurement of 6-Keto–prostaglandin F1α levels using an enzyme-linked immunosorbent assay (ELISA) kit (Cayman Chemical, Ann Arbor, MI, USA).
After filtering, the scientists uncovered 1,986 rare variants affecting 1,772 candidate genes. Most of these alterations were present only in a single person, but 15 genes were altered in three or more people. Of those, PTGIS, MACF1, GTF3C1, and ABCA3 are expressed in the lung. As PTGIS encodes prostaglandin synthase, which is involved in prostaglandin production, the team suspected it might be the most relevant of those 15 genes. In a replication cohort of 188 patients with IPAH, they uncovered additional patients with PTGIS variants. In all, 14 patients harbored one of three rare PTGIS variants.
The three rare PTGIS variants: A447T, R252Q, and c.521 +1G>A, are all located in conserved regions of the gene and are predicted by in silico analysis to be deleterious. Functional studies found that the PTGIS splicing variant affects the gene's transcription, as it led to exon skipping and an in-frame deletion. The two missense variants, meanwhile, led to impaired enzyme activity, decreased prostaglandin production, and increased cell death of pulmonary microvascular endothelial cells.
The authors concluded that they had identified three rare loss-of-function variants in the PTGIS gene from two independent cohorts with IPAH. The genetic variants of PTGIS predispose pulmonary vascular responses to the iloprost stimulation. These findings suggest that PTGIS variants may be involved in the pathogenesis of IPAH. The study was published on April 1, 2020 in the journal JAMA Cardiology.
Related Links:
Peking Union Medical College Hospital
Applied Biosystems
Cayman Chemical
Latest Pathology News
- AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
- AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
- Diagnostic Technology Performs Rapid Biofluid Analysis Using Single Droplet
- Novel Technology Tracks Hidden Cancer Cells Faster
- AI Tool Improves Breast Cancer Detection
- AI Tool Predicts Treatment Success in Rectal Cancer Patients
- Blood Test and Sputum Analysis Predict Acute COPD Exacerbation
- AI Tool to Transform Skin Cancer Detection with Near-Perfect Accuracy
- Unique Immune Signatures Distinguish Rare Autoimmune Condition from Multiple Sclerosis
- Simple Optical Microscopy Method Reveals Hidden Structures in Remarkable Detail
- Hydrogel-Based Technology Isolates Extracellular Vesicles for Early Disease Diagnosis
- AI Tool Improves Accuracy of Skin Cancer Detection
- Highly Sensitive Imaging Technique Detects Myelin Damage
- 3D Genome Mapping Tool to Improve Diagnosis and Treatment of Genetic Diseases
- New Molecular Analysis Tool to Improve Disease Diagnosis
- Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channelRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channelAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
Complex digital biopsy images that typically take an expert pathologist up to 20 minutes to assess can now be analyzed in about one minute using a new artificial intelligence (AI) tool. The technology... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








